<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-107477</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Management of pregnancy in patients with systemic lupus erythematosus</dc:title>
<dc:description xml:lang="en">Patients with systemic lupus eythematosus are exposed to a remarkably high number of maternal-fetal complications during pregnancy. Knowledge regarding the reciprocal influence between lupus and pregnancy is the starting point to assure that these patients are correctly monitored. It is also important to carry out comprehensive preconception evaluation to individually evaluate the risk of each patient. The immunological profile, history of nephritis, presence of chronic damage and disease activity are the basic data that will determine the specific individual risk profile. Finally, correct drug management must be assured during this period, based on the safety profile of the different treatments during pregnancy and lactation(AU)</dc:description>
<dc:creator>Ugarte, A</dc:creator>
<dc:creator>Villar, I</dc:creator>
<dc:creator>Ruiz-Irastorza, G</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las pacientes con lupus eritematoso sistémico están expuestas a un número no despreciable de potenciales complicaciones materno-fetales durante la gestación. El conocimiento de la influencia recíproca entre el lupus y el embarazo es un importante punto de partida para asegurar la correcta monitorización de las pacientes, así como lo es la realización de una exhaustiva valoración preconcepcional con el fin de evaluar de forma individualizada el riesgo de cada paciente. El perfil inmunológico, los antecedentes de nefropatía, la historia obstétrica previa, el daño crónico y la actividad son puntos clave que condicionarán el perfil de riesgo. Por último, es fundamental asegurar un correcto manejo farmacológico en este período, teniendo en cuenta el perfil de seguridad de los diversos tratamientos durante el embarazo y la lactancia(AU)</dc:description>
<dc:source>Rev Clin Esp;212(10): 491-498, nov.2012. tab, ilus</dc:source>
<dc:identifier>ibc-107477</dc:identifier>
<dc:title xml:lang="es">Manejo del embarazo en pacientes con lupus eritematoso sistémico</dc:title>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d11946^s22012</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d8356^s22057</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8356^s22012</dc:subject>
<dc:subject>^d11690^s22009</dc:subject>
<dc:subject>^d8356^s22032</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d30257^s22012</dc:subject>
<dc:subject>^d11690^s22016</dc:subject>
<dc:subject>^d11946^s22016</dc:subject>
<dc:subject>^d32857^s22045</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d22622^s22073</dc:subject>
<dc:subject>^d19233^s22032</dc:subject>
<dc:subject>^d19233^s22012</dc:subject>
<dc:subject>^d53815^s22045</dc:subject>
<dc:subject>^d1731^s22045</dc:subject>
<dc:subject>^d19233^s22016</dc:subject>
<dc:subject>^d1967^s22066</dc:subject>
<dc:subject>^d1967^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201211</dc:date>
</metadata>
</record>
</ibecs-document>
